1. Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
2. European medicines agency: tecvayli (teclistamab). Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli. Accessed December 19, 2022.
3. Teclistamab in Relapsed or Refractory Multiple Myeloma
4. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma. Accessed December 18, 2022.
5. The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies